CL2016000171A1 - Formulación de metaxalona. - Google Patents

Formulación de metaxalona.

Info

Publication number
CL2016000171A1
CL2016000171A1 CL2016000171A CL2016000171A CL2016000171A1 CL 2016000171 A1 CL2016000171 A1 CL 2016000171A1 CL 2016000171 A CL2016000171 A CL 2016000171A CL 2016000171 A CL2016000171 A CL 2016000171A CL 2016000171 A1 CL2016000171 A1 CL 2016000171A1
Authority
CL
Chile
Prior art keywords
metaxalone
formulation
metaxalone formulation
metaxalona
dosage form
Prior art date
Application number
CL2016000171A
Other languages
English (en)
Inventor
H William Bosch
Original Assignee
Iceutica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iceutica Inc filed Critical Iceutica Inc
Publication of CL2016000171A1 publication Critical patent/CL2016000171A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

FORMA DE DOSIFICACION UNITARIA DE METAXALONA.
CL2016000171A 2013-07-22 2016-01-22 Formulación de metaxalona. CL2016000171A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361857199P 2013-07-22 2013-07-22

Publications (1)

Publication Number Publication Date
CL2016000171A1 true CL2016000171A1 (es) 2016-07-01

Family

ID=52393794

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016000171A CL2016000171A1 (es) 2013-07-22 2016-01-22 Formulación de metaxalona.

Country Status (17)

Country Link
US (7) US20160159756A1 (es)
EP (1) EP3024440B1 (es)
JP (1) JP6453876B2 (es)
KR (1) KR20160039608A (es)
CN (1) CN105431136B (es)
AU (1) AU2014293193A1 (es)
BR (1) BR112016001395A8 (es)
CA (1) CA2918908A1 (es)
CL (1) CL2016000171A1 (es)
DK (1) DK3024440T3 (es)
IL (1) IL243447A0 (es)
MX (1) MX365591B (es)
MY (1) MY181226A (es)
RU (1) RU2684914C2 (es)
SG (2) SG10201800491RA (es)
WO (1) WO2015013336A1 (es)
ZA (1) ZA201600408B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
US20200405693A1 (en) * 2019-06-25 2020-12-31 Primus Pharmaceuticals, Inc. Reduced dose metaxalone formulations

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5500331A (en) 1994-05-25 1996-03-19 Eastman Kodak Company Comminution with small particle milling media
US5478705A (en) 1994-05-25 1995-12-26 Eastman Kodak Company Milling a compound useful in imaging elements using polymeric milling media
US6407128B1 (en) * 2001-12-03 2002-06-18 Elan Pharmaceuticals, Inc. Method for increasing the bioavailability of metaxalone
US7714006B1 (en) * 2001-12-03 2010-05-11 King Pharmaceuticals Research & Development, Inc. Methods of modifying the bioavailability of metaxalone
AU2003276688A1 (en) * 2002-09-02 2004-03-19 Sun Pharmaceutical Industries Limited Pharmaceutical composition of metaxalone with enhanced oral bioavailability
CA2534924A1 (en) * 2003-08-08 2005-02-24 Elan Pharma International Ltd. Novel metaxalone compositions
WO2005087204A1 (en) * 2004-03-08 2005-09-22 Spiridon Spireas Bioavailable solid dosage forms of metaxalone
WO2009019662A2 (en) * 2007-08-09 2009-02-12 Ranbaxy Laboratories Limited Oral metaxalone compositions
EP2421530B1 (en) * 2009-04-24 2019-08-21 Iceutica Pty Ltd. Formulation of metaxalone
IL254370B2 (en) * 2009-04-24 2023-12-01 Iceutica Pty Ltd Production of coated nanoparticles with a high particle volume
RU2499595C1 (ru) * 2012-07-03 2013-11-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко" Министерства здравоохранения и социального развития Российской Федерации Способ повышения качества жизни и улучшения способностей к выполнению профессиональной деятельности у пациентов с остеоартрозом, выполняющих водительские и диспетчерско-операторские функции

Also Published As

Publication number Publication date
US20220235017A1 (en) 2022-07-28
EP3024440B1 (en) 2018-11-28
US20160159756A1 (en) 2016-06-09
MX2016001019A (es) 2016-07-19
US20250084043A1 (en) 2025-03-13
CN105431136B (zh) 2020-03-24
DK3024440T3 (en) 2019-03-11
JP6453876B2 (ja) 2019-01-16
RU2016105763A (ru) 2017-08-29
EP3024440A4 (en) 2017-01-25
SG10201800491RA (en) 2018-03-28
JP2016527251A (ja) 2016-09-08
IL243447A0 (en) 2016-02-29
CA2918908A1 (en) 2015-01-29
MY181226A (en) 2020-12-21
US20190152930A1 (en) 2019-05-23
BR112016001395A2 (pt) 2017-07-25
RU2684914C2 (ru) 2019-04-16
ZA201600408B (en) 2017-04-26
SG11201600264TA (en) 2016-02-26
HK1225301A1 (en) 2017-09-08
KR20160039608A (ko) 2016-04-11
EP3024440A1 (en) 2016-06-01
MX365591B (es) 2019-06-07
BR112016001395A8 (pt) 2020-01-14
RU2016105763A3 (es) 2018-06-13
HK1222570A1 (zh) 2017-07-07
US20240150304A1 (en) 2024-05-09
CN105431136A (zh) 2016-03-23
AU2014293193A1 (en) 2016-01-28
US20180148422A1 (en) 2018-05-31
WO2015013336A1 (en) 2015-01-29
US20210101873A1 (en) 2021-04-08

Similar Documents

Publication Publication Date Title
CY1127391T1 (el) Σχηματα δοσολογιας ανοσοσυζευγματος εναντι- folr1
DK3030286T3 (da) Komfortabel patch-pumpe
FR3006466B3 (fr) .
PL3613453T3 (pl) Waporyzator
EP2967244A4 (en) ISSUE CONTAINER
BR112015029858A2 (pt) toalha sanitária
BR112015028572A2 (pt) ventilador axial
FR3011445B1 (fr) Chaussure
AR097668A1 (es) Colorante-polímero
ES2651188T8 (es) Composición líquida fotopolimerizable
FR3001302B1 (fr) .
BR112015024771A2 (pt) cateter
BR112015025165A2 (pt) veículo
BR112015029634A2 (pt) argamassa polimérica
UY4314Q (es) Configuracion aplicada en zapato
BR112015021575A2 (pt) composição fungicida
BR112016001395A2 (pt) forma de dosagem unitária oral sólida de metaxalona
FR3001303B1 (fr) .
DE112014005184A5 (de) Ausrückvorrichtung
DE112014001827A5 (de) Gleitschuh
TN2013000364A1 (fr) تصميم جديد لطائرة مدنية ذات مقعد واحد و انظمة سلامة متطورة
TN2013000282A1 (fr) الة لخدمة راس النخلة
TN2013000217A1 (fr) الطمي الاصطناعي لمقاومة التصحر
CL2016001839A1 (es) Formulación de suministro tópico
UA29903S (uk) Взуття